Welcome to our dedicated page for Marinus Pharmace news (Ticker: MRNS), a resource for investors and traders seeking the latest updates and insights on Marinus Pharmace stock.
Marinus Pharmaceuticals (MRNS) is a clinical-stage biopharma company advancing ganaxolone for rare neurological disorders, including epilepsy and CDKL5 deficiency disorder. This page aggregates official announcements and verified updates about the company's therapeutic developments and regulatory progress.
Investors and researchers will find timely updates on clinical trial outcomes, FDA designations, and strategic partnerships. Our curated collection ensures access to primary source materials including press releases, regulatory filings, and milestone achievements.
Key content includes updates on ganaxolone's development pathway, orphan drug status details, and analyses of the company's position in neurotherapeutics. All materials are sourced directly from company communications to ensure accuracy.
Bookmark this page for streamlined tracking of MRNS's progress in addressing high-need neurological conditions through innovative therapeutic development.
Marinus Pharmaceuticals (MRNS) reported updates on clinical and regulatory activities along with its 2020 financial results. The company ended 2020 with $140 million in cash after raising $70 million in December. They remain focused on submitting a New Drug Application (NDA) for ganaxolone in CDKL5 deficiency disorder and continuing Phase 3 trials for refractory status epilepticus (RSE) and tuberous sclerosis complex (TSC). Net losses for 2020 reached $67.5 million, up from $54.1 million in 2019, driven by increased research and development activities.
Marinus Pharmaceuticals (Nasdaq: MRNS) has unveiled a new brand identity symbolizing its commitment to patients and innovation in treating rare seizure disorders. The updated logo features interconnected rings representing various patient communities. Chief Commercial Officer Christy Shafer emphasized the company's evolution as a late-stage pharmaceutical entity. Marinus is enhancing its outreach through revamped communication channels, including its website and social media platforms, to raise awareness about its therapies and ongoing clinical programs, including pivotal trials for ganaxolone.
Marinus Pharmaceuticals (Nasdaq: MRNS) will present at key healthcare conferences, showcasing its commitment to treating rare seizure disorders. CEO Scott Braunstein, M.D., and CMO Joseph Hulihan, M.D., are scheduled to speak during the 10th Annual SVB Leerink Global Healthcare Conference on February 25 at 1:40 PM EST, followed by the Cowen 41st Annual Health Care Conference on March 1 at 10:20 AM EST. Additional presentations will occur at the H.C. Wainwright Global Life Sciences Conference on March 9 at 3:00 PM EST, and the Oppenheimer 31st Annual Healthcare Conference on March 16 at 8:00 AM EST.
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) announced the grant of inducement awards to five new employees, comprising non-qualified stock options for a total of 72,500 shares. The exercise prices range from $12.60 to $12.67 per share based on recent closing prices. These options will vest 25% after one year, with the remaining 75% vesting monthly over the next three years. Marinus is engaged in developing innovative therapeutics for rare seizure disorders, with ongoing Phase 3 and Phase 2 clinical trials for its lead product, ganaxolone.
Marinus Pharmaceuticals, Inc. (MRNS) plans to release its financial results for Q4 and FY 2020 on March 9, 2021, before the market opens. A conference call is scheduled for the same day at 8:30 AM ET to discuss these results and provide a business update. The company focuses on developing therapeutics for rare seizure disorders, with its lead product, Ganaxolone, proceeding through various clinical trials, including Phase 3 for status epilepticus and trials for CDKL5 deficiency disorder and tuberous sclerosis complex.
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) has initiated the enrollment of the first patient in a Phase 3 clinical trial for IV ganaxolone (RAISE trial) aimed at treating refractory status epilepticus (RSE), a critical condition involving severe, prolonged seizures. This randomized, double-blind, placebo-controlled study will assess the efficacy and safety of IV ganaxolone in patients who have not responded to standard treatments. The trial plans to include approximately 125 patients across 80 U.S. hospitals and is partially funded by BARDA.
Marinus Pharmaceuticals (Nasdaq: MRNS) received positive feedback from the FDA on the data from its pivotal Phase 3 Marigold Study for oral ganaxolone, aimed at treating children and young adults with CDKL5 deficiency disorder (CDD). The FDA deemed the efficacy and safety data sufficient to consider a New Drug Application (NDA) submission. The Marigold Study demonstrated a 32.2% reduction in major motor seizure frequency in patients treated with ganaxolone, achieving its primary endpoint. Marinus plans to hold a pre-NDA meeting by Q1's end and submit the NDA by mid-2021.
Marinus Pharmaceuticals (Nasdaq: MRNS) announced its participation in two major healthcare conferences. Management will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 3:40 pm EST. Additionally, they will join the H.C. Wainwright Bioconnect 2021 Conference starting January 11, 2021, at 6:00 am EST. Key speakers include CEO Scott Braunstein, CFO Edward Smith, and CMO Joseph Hulihan. Webcasts will be available post-event on the company’s website.
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) announced its inclusion in the Nasdaq Biotechnology Index (NBI), effective today. CEO Scott Braunstein emphasized that this recognition reflects the company's clinical progress and increasing investor awareness as they advance their pipeline targeting rare epilepsy and neuropsychiatric disorders. Marinus is focused on ganaxolone, a GABAA receptor modulator, which is being developed in various formulations for both adult and pediatric patients. They are conducting multiple clinical trials, including a pivotal Phase 3 trial for children with CDKL5 deficiency disorder.
Marinus Pharmaceuticals (Nasdaq: MRNS) announced an underwritten public offering of 5 million shares of common stock, aiming for gross proceeds of $70 million. The offering is expected to close around December 10, 2020, pending customary conditions. Cantor Fitzgerald is the sole bookrunner, with H.C. Wainwright as lead manager. Proceeds will support product candidate development and general corporate needs. The shares are offered under a shelf registration statement effective July 27, 2020. The last reported share price was $15.61 on December 7, 2020.
FAQ
What is the current stock price of Marinus Pharmace (MRNS)?
What is the market cap of Marinus Pharmace (MRNS)?
